Who are Cebranopadol 600 µg's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Korsuva, Viberzi, Transmucosal Buprenorphine, Subutex (SCH 028444), Sublingual Buprenorphine (SLB), High dose Oliceridine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cebranopadol-600-g.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Cebranopadol 600 µg — Competitive Intelligence Brief

Cebranopadol 600 µg (Cebranopadol 600 µg) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: opioid receptor agonist. Area: Pain management.

phase 2 opioid receptor agonist kappa opioid receptor, mu opioid receptor Pain management Small molecule Live · refreshed every 30 min

Target snapshot

Cebranopadol 600 µg (Cebranopadol 600 µg) — Tris Pharma, Inc.. Cebranopadol is a kappa opioid receptor agonist and mu opioid receptor agonist.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cebranopadol 600 µg TARGET	Cebranopadol 600 µg	Tris Pharma, Inc.	phase 2	opioid receptor agonist	kappa opioid receptor, mu opioid receptor
Korsuva	DIFELIKEFALIN	Vifor Intl	marketed	Kappa Opioid Receptor Agonist	Kappa-type opioid receptor	2021-01-01
Viberzi	ELUXADOLINE	AbbVie	marketed	mu-Opioid Receptor Agonist [EPC]	Mu-type opioid receptor	2015-01-01
Transmucosal Buprenorphine	Transmucosal Buprenorphine	Indivior Inc.	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)
Subutex (SCH 028444)	Subutex (SCH 028444)	Merck Sharp & Dohme LLC	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (OPRM1)
Sublingual Buprenorphine (SLB)	Sublingual Buprenorphine (SLB)	NYU Langone Health	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)
High dose Oliceridine	High dose Oliceridine	Nanjing First Hospital, Nanjing Medical University	marketed	Mu-opioid receptor agonist (biased agonist)	Mu-opioid receptor (OPRM1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (opioid receptor agonist class)

Tris Pharma, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cebranopadol 600 µg — Competitive Intelligence Brief. https://druglandscape.com/ci/cebranopadol-600-g. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab